Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MonitorMS

Financiado

Monitor Multiple Sclerosis evolution using body fluids derive cell-free epigenom...

Monitor Multiple Sclerosis evolution using body fluids derive cell-free epigenomics Multiple sclerosis (MS) affects 2.8 patients worldwide, 700000 in Europe alone, and is characterized by subsequent phases of different severity which eventually evolve into a chronic phase and untreatable paralysis. Current main d... ver más

31/08/2026

223K€

Presupuesto del proyecto: 223K€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-15

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

222.73K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCIN-2015-021 NANO-AMPLIFICADOR UNIVERSAL PARA EL MULTIANALISIS DE MICROAR... 100K€ Cerrado

EpiCblood Towards early cancer detection and tumor classification usin... 1M€ Cerrado

EQC2018-004322-P Equipamiento para una plataforma de estudio molecular del Ge... 148K€ Cerrado

EQC2018-005252-P EQUIPAMIENTO ANÁLISIS MOLECULAR 255K€ Cerrado

EQC2021-006895-P Espectrómetro de masas para la medida multiparamétrica simu... 525K€ Cerrado

CSIC08-3E-035 Adquisición de un equipo de Análisis genético de segunda gen... 562K€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2024-04-15
Fecha Fin: 2026-08-31

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 223K€

Descripción del proyecto Multiple sclerosis (MS) affects 2.8 patients worldwide, 700000 in Europe alone, and is characterized by subsequent phases of different severity which eventually evolve into a chronic phase and untreatable paralysis. Current main diagnostic approaches are limited to symptom evaluation and imaging, underlying a lack of informative and reliable biomarkers. MonitorMS aims to test the use of cell-free Chromatin (cfChromatin) present in the plasma and cerebrospinal fluid (CSF) as a new biomarker to monitor the progression of MS pathology and response to treatment. The proposal includes the development of a new technology based on nanoCut&Tag(nanoCT) to improve and simplify the current methodology used to profile cfChromatin. Recently, it has been demonstrated that cell-free DNA in plasma is still wrapped around histones which still preserve the presence of post-translational modifications, termed cfChromatin. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) has been recently used to profile cfChromatin from plasma of patients affected by liver, and heart damage or cancer showing a pathology and stage-specific signature. To decode the information inside cfChromatin a reference dataset is needed. The first aim of MonitorMS is to develop a protocol to profile cfChromatin from plasma/cell-free CSF with nanoCT and compare it to the actual reference (ChIP-seq). In the second phase, the technology will be employed on a larger cohort of samples from a KI biobank, including patients under immunosuppressant treatment. Simultaneously a single-cell multimodal dataset, from matched MS patients' immune cells and post-mortem tissues, will be generated to deconvolve the informative content of cfChromatin. The final phase of the project will include further integration of the generated cfChromatin data with several MS single-cell transcriptome and spatial data. Finally, machine learning will be used to test cfChromatin as a stage/treatment-specific biomarker in MS.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores